GLP-1 medicine for heart artery health after angioplasty
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests how a new type of diabetes medicine, called a GLP-1 receptor agonist, affects heart artery health in people with type 2 diabetes who recently had a heart procedure. It aims to find out if adding this medicine can further protect the heart and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 20 years old
- You must have type 2 diabetes and have had a heart artery opening procedure (angioplasty) in the last 3 months
- You must currently be taking an SGLT2 inhibitor medicine (like empagliflozin or dapagliflozin)
- You cannot be pregnant
- Your kidney function must be good (eGFR of 30 or higher)
- You must not have used a GLP-1 agonist medicine (like semaglutide or liraglutide) in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether a GLP-1 receptor agonist (a medication used for diabetes and weight loss) can reduce heart damage during or after planned non-cardiac surgery. It may help patients with heart risk undergoing intermediate to high-risk procedures.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Hear when a new Glucagon-Like Peptide-1 Receptor Agonists trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.